source
- Sanofi halts rare disease trial as Parabilis launches record biotech IPO amid European pricing debateSanofi announced it is stopping a Phase 3 trial of its experimental drug riliprubart in a rare autoimmune disease after an interim analysis showed the treatment did not work. The pause adds to rec…
- Shattuck Labs raises $75M in public offering, selling 10.5M shares at $4 eachShattuck Labs announced a $75 million public offering to raise capital. The company is selling more than 10.5 million shares at $4 per share and is also issuing pre‑funded warrants to selected inv…